At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Retapamulin Ointment, 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months
In Brief
A Phase 4 clinical trial evaluating Retapamulin Ointment, 1% for Skin Infections, Bacterial. Completed, enrolled 60 participants across 25 sites in 9 countries.
Detailed Summary
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Infections, Bacterial
CountriesArgentina, Chile, Costa Rica, Germany, Mexico, Netherlands, South Africa, Taiwan, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedNov 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedNov 7, 2007
Enrollment StartSep 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.7 years ago
Interventions
Retapamulin Ointment, 1%drug
1% Ointment